Reuters logo
8 months ago
BRIEF-Celgene says will not take tnAcity trial testing ABRAXANE+chemotherapy regimen into ph 3
December 7, 2016 / 12:55 PM / 8 months ago

BRIEF-Celgene says will not take tnAcity trial testing ABRAXANE+chemotherapy regimen into ph 3

1 Min Read

Dec 7 (Reuters) - Celgene Corp:

* Celgene - results of its randomized phase ii tnAcity trial of ABRAXANE for injectable suspension

* Celgene - data shows ABRAXANE + carboplatin regimen experienced longer median treatment duration versus with ABRAXANE + gemcitabine or carboplatin + gemcitabine regimen

* Celgene had determined not to move forward with phase iii portion of tnAcity

* Celgene- Weekly combination of ABRAXANE+carboplatin had longer PFS versus weekly regimens of ABRAXANE+gemcitabine/ or of carboplatin+gemcitabine in mntbc patients

* Celgene - percentage of patients that discontinued any study drug due to a teae was 45% for ABRAXANE + carboplatin and 25% for each of other arms

* Celgene - will instead focus its breast cancer research support on ABRAXANE/ immunotherapy combinations Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below